Deep Longevity Company Profile

Background

Deep Longevity, founded in 2019 and headquartered in Hong Kong, specializes in developing artificial intelligence (AI) systems to monitor and influence the aging process. The company's mission is to extend human healthspan and lifespan by providing tools that assess biological and psychological aging, thereby enabling personalized interventions to promote longevity.

Key Strategic Focus

Deep Longevity's strategic focus centers on creating explainable AI systems that track aging at various biological levels, including molecular, cellular, tissue, organ, system, physiological, and psychological. Their core objectives include:

Development of Aging Clocks: Creating deep biomarkers of aging, known as "deep aging clocks," to provide a comprehensive measure of human biological age.

Longevity as a Service (LaaS): Offering a platform that integrates multiple aging biomarkers to assist healthcare providers in making informed decisions about interventions that may slow or reverse aging processes.

Psychological Aging Assessment: Introducing tools like MindAge© to evaluate psychological aging, recognizing the impact of mental health on overall longevity.

Financials and Funding

In September 2020, Deep Longevity was acquired by Regent Pacific Group Limited (now Endurance RP Limited) for approximately HK$29.56 million (US$3.79 million). Prior to this acquisition, the company secured Series A funding from notable investors specializing in biotechnology, longevity, and AI, including:

BOLD Capital Partners

ETP Ventures

Human Longevity and Performance Impact Venture Fund

Longevity Vision Fund

LongeVC

Michael Antonov (co-founder of Oculus VR)

These investments have been utilized to advance the development of AI-driven aging clocks and expand the company's product offerings.

Pipeline Development

Deep Longevity has developed several key products:

Blood Age: An AI-driven tool that analyzes blood test data to estimate biological age and provide health recommendations.

Mind Age: A psychological assessment framework that calculates an individual's psychological age through proprietary questionnaires.

SenoClock: A SaaS platform offering access to various aging clocks, facilitating personalized health insights and preventive care strategies.

Technological Platform and Innovation

Deep Longevity's innovation is rooted in its proprietary AI technologies:

Deep Aging Clocks: AI models trained on diverse datasets to predict biological age and assess the effectiveness of anti-aging interventions.

Microbiomic Aging Clock: A patented AI system that estimates biological age based on gut microbiome composition, with applications in personalized nutrition and health optimization.

Psychological Aging Clocks: Tools like MindAge© that evaluate psychological age, emphasizing the role of mental health in overall aging.

Leadership Team

Alex Zhavoronkov, PhD: Founder and Chief Longevity Officer. A visionary in AI and longevity, he has spearheaded the development of aging clocks and statistical models integral to longevity research.

Leadership Changes

In August 2022, Deep Longevity was acquired by Endurance RP Limited, leading to strategic realignments within the leadership team to integrate the company's operations and objectives.

Competitor Profile

Market Insights and Dynamics

The longevity biotechnology market is experiencing significant growth, driven by advancements in AI, genomics, and personalized medicine. The increasing global aging population and rising interest in healthspan extension contribute to the market's expansion.

Competitor Analysis

Key competitors include:

Calico: A research and development company focusing on understanding the biology of aging to develop interventions that enable people to lead longer and healthier lives.

Verily Life Sciences: Engages in research and development of tools and platforms to collect, organize, and activate health data, with a focus on precision health.

Life Biosciences: Concentrates on addressing the eight pathways of age-related decline to develop therapies that improve healthspan.

Strategic Collaborations and Partnerships

Deep Longevity has established significant partnerships to enhance its market position and innovation capacity:

Ani Biome: Collaborated to develop gut health-management tools leveraging Deep Longevity's Blood Age and Mind Age clock APIs.

Longenesis: Partnered to integrate consent management systems and develop a federated learning framework for aging research.

Human Longevity, Inc.: Established a research partnership to provide a range of aging clocks to a network of advanced physicians and researchers.

Operational Insights

Deep Longevity differentiates itself through its AI-driven approach to aging assessment, offering a comprehensive suite of tools that address both biological and psychological aspects of aging. This holistic perspective provides a competitive advantage in the longevity biotechnology market.

Strategic Opportunities and Future Directions

The company aims to:

Expand Product Offerings: Develop additional aging clocks and health assessment tools to address various aspects of aging.

Enhance AI Capabilities: Invest in advanced AI methodologies to improve the accuracy and applicability of aging assessments.

Broaden Market Reach: Establish partnerships with healthcare providers, insurance companies, and wellness organizations to integrate aging clocks into mainstream health management practices.